DB
OVID icon

Dmitry Balyasny’s Ovid Therapeutics OVID Stock Holding History

Dmitry Balyasny’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1M Buy
6,719,076
+1,186,003
+21% +$3.06M 0.02% 776
2026
Q1 		$12.3M Buy
5,533,073
+5,208,073
+1,602% +$9.31M 0.02% 940
2025
Q4 		$530K Sell
325,000
-300,000
-48% -$462K ﹤0.01% 2503
2025
Q3 		$813K Buy
+625,000
New +$542K ﹤0.01% 2206
2023
Q2 		– Sell
-24,056
Closed -$62.1K – 2651
2023
Q1 		$62.1K Buy
+24,056
New +$57K ﹤0.01% 2364
2022
Q4 		– Sell
-31,938
Closed -$59K – 3113
2022
Q3 		$59K Buy
+31,938
New +$66.8K ﹤0.01% 2457

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Dmitry Balyasny's OVID Position: Q2 2026 in Review

Dmitry Balyasny increased its Ovid Therapeutics (OVID) stake by 21% in Q2 2026, buying an estimated $3.06M and bringing the position to 6,719,076 shares worth $18.1M. The position accounts for 0.02% of the portfolio, ranked #776.

Dmitry Balyasny first reported a position in OVID in Q3 2022 and has held it in 6 quarters since. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Dmitry Balyasny held 6,719,076 shares of Ovid Therapeutics worth $18.1M as of Q2 2026.
  • Dmitry Balyasny bought 1,186,003 Ovid Therapeutics shares in Q2 2026, an estimated $3.06M.
  • Ovid Therapeutics made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #776 holding.
  • Dmitry Balyasny first reported a position in Ovid Therapeutics in Q3 2022 and has held it in 6 quarters since.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.